19 recherche sur le mot-clé 'Attention Deficit Disorder with Hyperactivity'

Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability / Emily SIMONOFF in Journal of Child Psychology and Psychiatry, 54-5 (May 2013)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 54-5 (May 2013) . - p.527-535 Titre : Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability Type de document : Texte imprimé et/ou numérique Auteurs : Emily SIMONOFF, Auteur ; Eric TAYLOR, Auteur ; Gillian BAIRD, Auteur ; Sarah BERNARD, Auteur ; Oliver CHADWICK, Auteur ; Holan LIANG, Auteur ; Susannah WHITWELL, Auteur ; Kirsten RIEMER, Auteur ; Kishan SHARMA, Auteur ; Santvana Pandey SHARMA, Auteur ; Nicky WOOD, Auteur ; Joanna KELLY, Auteur ; Ania GOLASZEWSKI, Auteur ; Juliet KENNEDY, Auteur ; Lydia RODNEY, Auteur ; Nicole WEST, Auteur ; Rebecca WALWYN, Auteur ; Fatima JICHI, Auteur Article en page(s) : p.527-535 Langues : Anglais (eng) Mots-clés : Attention deficit disorder with hyperactivity  Randomized controlled trial  autism  mental retardation  intellectual disability  methylphenidate  stimulants Index. décimale : PER Périodiques Résumé : Background: Attention deficit hyperactivity disorder is increased in children with intellectual disability. Previous research has suggested stimulants are less effective than in typically developing children but no studies have titrated medication for individual optimal dosing or tested the effects for longer than 4 weeks. Method: One hundred and twenty two drug-free children aged 7–15 with hyperkinetic disorder and IQ 30–69 were recruited to a double-blind, placebo-controlled trial that randomized participants using minimization by probability, stratified by referral source and IQ level in a one to one ratio. Methylphenidate was compared with placebo. Dose titration comprised at least 1 week each of low (0.5 mg/kg/day), medium (1.0 mg/kg/day) and high dose (1.5 mg/kg/day). Parent and teacher Attention deficit hyperactivity disorder (ADHD) index of the Conners Rating Scale-Short Version at 16 weeks provided the primary outcome measures. Clinical response was determined with the Clinical Global Impressions scale (CGI-I). Adverse effects were evaluated by a parent-rated questionnaire, weight, pulse and blood pressure. Analyses were by intention to treat. Trial registration: ISRCTN 68384912. Results: Methylphenidate was superior to placebo with effect sizes of 0.39 [95% confidence intervals (CIs) 0.09, 0.70] and 0.52 (95% CIs 0.23, 0.82) for the parent and teacher Conners ADHD index. Four (7%) children on placebo versus 24 (40%) of those on methylphenidate were judged improved or much improved on the CGI. IQ and autistic symptoms did not affect treatment efficacy. Active medication was associated with sleep difficulty, loss of appetite and weight loss but there were no significant differences in pulse or blood pressure. Conclusions: Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability. Adverse effects typical of methylphenidate were seen and medication use may require close monitoring in this vulnerable group. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2012.02569.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=196 [article] Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability [Texte imprimé et/ou numérique] / Emily SIMONOFF, Auteur ; Eric TAYLOR, Auteur ; Gillian BAIRD, Auteur ; Sarah BERNARD, Auteur ; Oliver CHADWICK, Auteur ; Holan LIANG, Auteur ; Susannah WHITWELL, Auteur ; Kirsten RIEMER, Auteur ; Kishan SHARMA, Auteur ; Santvana Pandey SHARMA, Auteur ; Nicky WOOD, Auteur ; Joanna KELLY, Auteur ; Ania GOLASZEWSKI, Auteur ; Juliet KENNEDY, Auteur ; Lydia RODNEY, Auteur ; Nicole WEST, Auteur ; Rebecca WALWYN, Auteur ; Fatima JICHI, Auteur . - p.527-535. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 54-5 (May 2013) . - p.527-535 Mots-clés : Attention deficit disorder with hyperactivity  Randomized controlled trial  autism  mental retardation  intellectual disability  methylphenidate  stimulants Index. décimale : PER Périodiques Résumé : Background: Attention deficit hyperactivity disorder is increased in children with intellectual disability. Previous research has suggested stimulants are less effective than in typically developing children but no studies have titrated medication for individual optimal dosing or tested the effects for longer than 4 weeks. Method: One hundred and twenty two drug-free children aged 7–15 with hyperkinetic disorder and IQ 30–69 were recruited to a double-blind, placebo-controlled trial that randomized participants using minimization by probability, stratified by referral source and IQ level in a one to one ratio. Methylphenidate was compared with placebo. Dose titration comprised at least 1 week each of low (0.5 mg/kg/day), medium (1.0 mg/kg/day) and high dose (1.5 mg/kg/day). Parent and teacher Attention deficit hyperactivity disorder (ADHD) index of the Conners Rating Scale-Short Version at 16 weeks provided the primary outcome measures. Clinical response was determined with the Clinical Global Impressions scale (CGI-I). Adverse effects were evaluated by a parent-rated questionnaire, weight, pulse and blood pressure. Analyses were by intention to treat. Trial registration: ISRCTN 68384912. Results: Methylphenidate was superior to placebo with effect sizes of 0.39 [95% confidence intervals (CIs) 0.09, 0.70] and 0.52 (95% CIs 0.23, 0.82) for the parent and teacher Conners ADHD index. Four (7%) children on placebo versus 24 (40%) of those on methylphenidate were judged improved or much improved on the CGI. IQ and autistic symptoms did not affect treatment efficacy. Active medication was associated with sleep difficulty, loss of appetite and weight loss but there were no significant differences in pulse or blood pressure. Conclusions: Optimal dosing of methylphenidate is practical and effective in some children with hyperkinetic disorder and intellectual disability. Adverse effects typical of methylphenidate were seen and medication use may require close monitoring in this vulnerable group. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2012.02569.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=196

Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder / Anne B. ARNETT in Journal of Child Psychology and Psychiatry, 63-12 (December 2022)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 63-12 (December 2022) . - p.1615-1621 Titre : Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder Type de document : Texte imprimé et/ou numérique Auteurs : Anne B. ARNETT, Auteur ; Margaret FEAREY, Auteur ; Virginia PEISCH, Auteur ; April R. LEVIN, Auteur Article en page(s) : p.1615-1621 Langues : Anglais (eng) Mots-clés : Child  Female  Humans  Male  Attention Deficit Disorder with Hyperactivity  Electroencephalography  Brain  Adhd  Eeg  cognition  neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Prior research suggests that symptoms of attention deficit hyperactivity disorder (ADHD) and related neurodevelopmental disorders may derive from alterations in the brain's ability to flexibly tune the balance between information integration and segregation and global versus local processing. This balance allows the brain to optimally filter salient stimuli in the environment and can be measured with electroencephalography (EEG) via calculation of the aperiodic spectral slope. A steeper aperiodic slope increases the capacity of global neural networks to process low-salience stimuli, while a flatter aperiodic slope reflects an emphasis on local neural networks that respond preferentially to high-salience input. Although aperiodic slope differences have been reported in ADHD, prior studies have not accounted for differing levels of stimulus input in experimental paradigms. There is evidence to suggest that dynamic shifts in neural oscillation patterns in response to changing environmental conditions could be critical for attention regulation. METHODS: Using high-density resting EEG, we measured aperiodic spectral slope during low contrast (lights off) and high contrast (lights on) environmental conditions in a sample of 88 7-11-year-old children diagnosed with ADHD and 29 controls (30% female). RESULTS: While controls showed a flatter aperiodic slope during the high contrast (lights on) as compared to low contrast (lights off) environmental condition, children with ADHD did not show any change in aperiodic slope across conditions. CONCLUSIONS: This study presents a novel etiological model of biological mechanisms associated with ADHD. Children with ADHD show suboptimal modulation of intrinsic neural activity in response to changing environmental input. The dynamic spectral slope is a promising candidate biomarker for ADHD. The possibility that dynamic spectral slope is associated with cognitive-behavioral regulation more broadly merits further investigation. En ligne : http://dx.doi.org/10.1111/jcpp.13645 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490 [article] Absence of dynamic neural oscillatory response to environmental conditions marks childhood attention deficit hyperactivity disorder [Texte imprimé et/ou numérique] / Anne B. ARNETT, Auteur ; Margaret FEAREY, Auteur ; Virginia PEISCH, Auteur ; April R. LEVIN, Auteur . - p.1615-1621. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 63-12 (December 2022) . - p.1615-1621 Mots-clés : Child  Female  Humans  Male  Attention Deficit Disorder with Hyperactivity  Electroencephalography  Brain  Adhd  Eeg  cognition  neurodevelopmental disorders Index. décimale : PER Périodiques Résumé : BACKGROUND: Prior research suggests that symptoms of attention deficit hyperactivity disorder (ADHD) and related neurodevelopmental disorders may derive from alterations in the brain's ability to flexibly tune the balance between information integration and segregation and global versus local processing. This balance allows the brain to optimally filter salient stimuli in the environment and can be measured with electroencephalography (EEG) via calculation of the aperiodic spectral slope. A steeper aperiodic slope increases the capacity of global neural networks to process low-salience stimuli, while a flatter aperiodic slope reflects an emphasis on local neural networks that respond preferentially to high-salience input. Although aperiodic slope differences have been reported in ADHD, prior studies have not accounted for differing levels of stimulus input in experimental paradigms. There is evidence to suggest that dynamic shifts in neural oscillation patterns in response to changing environmental conditions could be critical for attention regulation. METHODS: Using high-density resting EEG, we measured aperiodic spectral slope during low contrast (lights off) and high contrast (lights on) environmental conditions in a sample of 88 7-11-year-old children diagnosed with ADHD and 29 controls (30% female). RESULTS: While controls showed a flatter aperiodic slope during the high contrast (lights on) as compared to low contrast (lights off) environmental condition, children with ADHD did not show any change in aperiodic slope across conditions. CONCLUSIONS: This study presents a novel etiological model of biological mechanisms associated with ADHD. Children with ADHD show suboptimal modulation of intrinsic neural activity in response to changing environmental input. The dynamic spectral slope is a promising candidate biomarker for ADHD. The possibility that dynamic spectral slope is associated with cognitive-behavioral regulation more broadly merits further investigation. En ligne : http://dx.doi.org/10.1111/jcpp.13645 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490

Association Between Prematurity and Diagnosis of Neurodevelopment Disorder: A Case-Control Study / Thaise C B SONCINI in Journal of Autism and Developmental Disorders, 50-1 (January 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-1 (January 2020) . - p.145-152 Titre : Association Between Prematurity and Diagnosis of Neurodevelopment Disorder: A Case-Control Study Type de document : Texte imprimé et/ou numérique Auteurs : Thaise C B SONCINI, Auteur ; Gabriella Antunes BELOTTO, Auteur ; Alexandre P. DIAZ, Auteur Article en page(s) : p.145-152 Langues : Anglais (eng) Mots-clés : Attention deficit disorder with hyperactivity  Autism spectrum disorder  Infant  Neurodevelopmental disorders  Premature Index. décimale : PER Périodiques Résumé : The aim of this study is to investigate the association between prematurity and diagnosis of neurodevelopmental disorders (ND) (attention deficit/hyperactivity disorder [ADHD] or autism spectrum disorder [ASD]) in Brazilian children and adolescents. Case-control study based on medical records data from a specialized outpatient clinic. Prematurity was defined as gestational age less than 37 weeks. Prematurity was independently associated with diagnosis of a ND (adjusted odds ratio [AOR] 3.46, 95% CI 1.15 - 7.92), as well as with ADHD and ASD diagnosis after a multiple logistic regression analysis. These findings from Brazilian patients are related to what is found in the literature worldwide. Efforts to modify risk factors, such as prematurity, may impact incidence reduction of both ADHD and ASD. En ligne : http://dx.doi.org/10.1007/s10803-019-04235-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=414 [article] Association Between Prematurity and Diagnosis of Neurodevelopment Disorder: A Case-Control Study [Texte imprimé et/ou numérique] / Thaise C B SONCINI, Auteur ; Gabriella Antunes BELOTTO, Auteur ; Alexandre P. DIAZ, Auteur . - p.145-152. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-1 (January 2020) . - p.145-152 Mots-clés : Attention deficit disorder with hyperactivity  Autism spectrum disorder  Infant  Neurodevelopmental disorders  Premature Index. décimale : PER Périodiques Résumé : The aim of this study is to investigate the association between prematurity and diagnosis of neurodevelopmental disorders (ND) (attention deficit/hyperactivity disorder [ADHD] or autism spectrum disorder [ASD]) in Brazilian children and adolescents. Case-control study based on medical records data from a specialized outpatient clinic. Prematurity was defined as gestational age less than 37 weeks. Prematurity was independently associated with diagnosis of a ND (adjusted odds ratio [AOR] 3.46, 95% CI 1.15 - 7.92), as well as with ADHD and ASD diagnosis after a multiple logistic regression analysis. These findings from Brazilian patients are related to what is found in the literature worldwide. Efforts to modify risk factors, such as prematurity, may impact incidence reduction of both ADHD and ASD. En ligne : http://dx.doi.org/10.1007/s10803-019-04235-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=414

Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis / Spyridon SIAFIS in Molecular Autism, 13 (2022)  

Public ISBD [article]  inMolecular Autism > 13 (2022) . - 10 p. Titre : Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Adolescent  Adult  Attention Deficit Disorder with Hyperactivity  Autism Spectrum Disorder/drug therapy  Child  Humans  Network Meta-Analysis  Oxytocin/therapeutic use  Risperidone/therapeutic use  Adhd  Anxiety  Autism  Caregiver stress  Irritability  Meta-analysis  Response  Restricted and repetitive behaviors  Social communication  Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477 [article] Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis [Texte imprimé et/ou numérique] / Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur . - 10 p. Langues : Anglais (eng) in Molecular Autism > 13 (2022) . - 10 p. Mots-clés : Adolescent  Adult  Attention Deficit Disorder with Hyperactivity  Autism Spectrum Disorder/drug therapy  Child  Humans  Network Meta-Analysis  Oxytocin/therapeutic use  Risperidone/therapeutic use  Adhd  Anxiety  Autism  Caregiver stress  Irritability  Meta-analysis  Response  Restricted and repetitive behaviors  Social communication  Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477

Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial / Yun WANG in Journal of Child Psychology and Psychiatry, 63-11 (November 2022)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 63-11 (November 2022) . - p.1381-1391 Titre : Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial Type de document : Texte imprimé et/ou numérique Auteurs : Yun WANG, Auteur ; Ellen KESSEL, Auteur ; Seonjoo LEE, Auteur ; Susie HONG, Auteur ; Elizabeth RAFFANELLO, Auteur ; Leslie A. HULVERSHORN, Auteur ; Amy MARGOLIS, Auteur ; Bradley S. PETERSON, Auteur ; Jonathan POSNER, Auteur Article en page(s) : p.1381-1391 Langues : Anglais (eng) Mots-clés : Adolescent  Humans  Child  Young Adult  Adult  Lisdexamfetamine Dimesylate/pharmacology/therapeutic use  Central Nervous System Stimulants/pharmacology  Attention Deficit Disorder with Hyperactivity  Brain Mapping  Brain/diagnostic imaging  Magnetic Resonance Imaging  Adhd  Dynamic Functional MRI (fMRI)  Lisdexamfetamine  Striatum  Structural Equation Modeling  Thalamus Index. décimale : PER Périodiques Résumé : BACKGROUND: Psychostimulants are frequently used to treat attention-deficit/hyperactivity disorder (ADHD), but side effects are common leading to many patients discontinuing treatment. Identifying neural mechanisms by which psychostimulants attenuate symptoms may guide the development of more refined and tolerable therapeutics. METHODS: We conducted a 12-week, randomized, placebo-controlled trial (RCT) of a long-acting amphetamine, lisdexamfetamine (LDEX), in patients with ADHD, ages 6-25 years old. Of the 58 participants who participated in the RCT, 49 completed pre- and post-RCT magnetic resonance imaging scanning with adequate data quality. Healthy controls (HCs; n=46) were included for comparison. Treatment effects on striatal and thalamic functional connectivity (FC) were identified using static (time-averaged) and dynamic (time-varying) measures and then correlated with symptom improvement. Analyses were repeated in independent samples from the Adolescent Brain Cognitive Development study (n=103) and the ADHD-200 Consortium (n=213). RESULTS: In 49 participants (25 LDEX; 24 Placebo), LDEX increased static and decreased dynamic FC (DFC). However, only DFC was associated with the therapeutic effects of LDEX. Additionally, at baseline, DFC was elevated in unmedicated-ADHD participants relative to HCs. Independent samples yielded similar findings - ADHD was associated with increased DFC, and psychostimulants with reduced DFC. Static FC findings were inconsistent across samples. CONCLUSIONS: Changes in dynamic, but not static, FC were associated with the therapeutic effects of psychostimulants. While prior research has focused on static FC, DFC may offer a more reliable target for new ADHD interventions aimed at stabilizing network dynamics, though this needs confirmation with subsequent investigations. En ligne : http://dx.doi.org/10.1111/jcpp.13585 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490 [article] Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial [Texte imprimé et/ou numérique] / Yun WANG, Auteur ; Ellen KESSEL, Auteur ; Seonjoo LEE, Auteur ; Susie HONG, Auteur ; Elizabeth RAFFANELLO, Auteur ; Leslie A. HULVERSHORN, Auteur ; Amy MARGOLIS, Auteur ; Bradley S. PETERSON, Auteur ; Jonathan POSNER, Auteur . - p.1381-1391. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 63-11 (November 2022) . - p.1381-1391 Mots-clés : Adolescent  Humans  Child  Young Adult  Adult  Lisdexamfetamine Dimesylate/pharmacology/therapeutic use  Central Nervous System Stimulants/pharmacology  Attention Deficit Disorder with Hyperactivity  Brain Mapping  Brain/diagnostic imaging  Magnetic Resonance Imaging  Adhd  Dynamic Functional MRI (fMRI)  Lisdexamfetamine  Striatum  Structural Equation Modeling  Thalamus Index. décimale : PER Périodiques Résumé : BACKGROUND: Psychostimulants are frequently used to treat attention-deficit/hyperactivity disorder (ADHD), but side effects are common leading to many patients discontinuing treatment. Identifying neural mechanisms by which psychostimulants attenuate symptoms may guide the development of more refined and tolerable therapeutics. METHODS: We conducted a 12-week, randomized, placebo-controlled trial (RCT) of a long-acting amphetamine, lisdexamfetamine (LDEX), in patients with ADHD, ages 6-25 years old. Of the 58 participants who participated in the RCT, 49 completed pre- and post-RCT magnetic resonance imaging scanning with adequate data quality. Healthy controls (HCs; n=46) were included for comparison. Treatment effects on striatal and thalamic functional connectivity (FC) were identified using static (time-averaged) and dynamic (time-varying) measures and then correlated with symptom improvement. Analyses were repeated in independent samples from the Adolescent Brain Cognitive Development study (n=103) and the ADHD-200 Consortium (n=213). RESULTS: In 49 participants (25 LDEX; 24 Placebo), LDEX increased static and decreased dynamic FC (DFC). However, only DFC was associated with the therapeutic effects of LDEX. Additionally, at baseline, DFC was elevated in unmedicated-ADHD participants relative to HCs. Independent samples yielded similar findings - ADHD was associated with increased DFC, and psychostimulants with reduced DFC. Static FC findings were inconsistent across samples. CONCLUSIONS: Changes in dynamic, but not static, FC were associated with the therapeutic effects of psychostimulants. While prior research has focused on static FC, DFC may offer a more reliable target for new ADHD interventions aimed at stabilizing network dynamics, though this needs confirmation with subsequent investigations. En ligne : http://dx.doi.org/10.1111/jcpp.13585 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=490

A co-twin-control study of altered sensory processing in autism / Janina NEUFELD in Autism, 25-5 (July 2021)  

Permalink

A co-twin-control study of altered sensory processing in autism / Janina NEUFELD in Autism, 26-5 (July 2022)  

Permalink

Depression in 3/6-year-old children: clinical and psychosocial outcomes in later childhood and adolescence / Jamilah SILVER in Journal of Child Psychology and Psychiatry, 63-9 (September 2022)  

Permalink

Editorial Perspective: Perils and promise for child and adolescent sleep and associated psychopathology during the COVID-19 pandemic / Stephen P. BECKER in Journal of Child Psychology and Psychiatry, 61-7 (July 2020)  

Permalink

Longitudinal relations between impaired executive function and symptoms of psychiatric disorders in childhood / Marte HALSE in Journal of Child Psychology and Psychiatry, 63-12 (December 2022)  

Permalink